Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SonoCloud and carboplatin in recurrent glioblastoma
NCT02253212Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2014
- Primary completion
- Jul 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin in glioblastoma (GBM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Safety of transient disruption of the blood-brain barrier at 12 months. Started Jul 2014; status: completed.
02
Drugs
carboplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02253212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253212.